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ORIGINAL ARTICLE
Phase II Study of Cediranib (AZD 2171), an Inhibitor of
the Vascular Endothelial Growth Factor Receptor, for
Second-Line Therapy of Small Cell Lung Cancer
(National Cancer Institute #7097)
Suresh S. Ramalingam, MD,* Chandra P. Belani, MD,† Philip C. Mack, PhD,‡
Everett E. Vokes, MD,§ Jeffrey Longmate, PhD, Ramaswamy Govindan, MD,¶
Marianna Koczywas, MD,** S. Percy Ivy, MD,# and David R. Gandara, MD‡
Background: Inhibition of angiogenesis is a novel strategy for the
treatment of cancer. We evaluated the safety and efficacy of
cediranib, a potent small molecule inhibitor of the vascular endo-
thelial growth factor receptor, in patients with refractory or recurrent
small cell lung cancer (SCLC).
Methods: Patients with SCLC with progression after prior plati-
num-based chemotherapy only; performance status (PS) of 0 to 2;
and adequate bone marrow, renal, and hepatic function were in-
cluded. The dose of cediranib was 45 mg PO once a day for the first
12 patients and was reduced to 30 mg PO once a day for the
subsequent patients because of intolerance of the higher dose.
Treatment was given on a daily continuous schedule. The primary
end point was determination of the response rate.
Results: Twenty-five patients were enrolled. Patient characteristics
were as follows: 13 men; median age 61 years; PS 0 (12 pts), PS 1
(12 pts). A median of two cycles were administered. Salient grade
3/4 toxicities were fatigue, diarrhea, hypertension, proteinuria, and
elevated liver enzymes. Tolerability was better with the 30 mg dose
once a day. Nine patients had stable disease, but none had a
confirmed partial response. The median progression-free survival
and overall survival were 2 and 6 months, respectively. Response
criteria to proceed to full accrual were not met. Increase in circu-
lating endothelial cell count was noted at the time of progression in
several patients.
Conclusions: Cediranib failed to demonstrate objective responses in
recurrent or refractory SCLC at the dose and schedule evaluated.
The 45 mg dose was intolerable in a majority of SCLC patients.
Key Words: Angiogenesis, Small cell lung cancer, Cediranib,
Biomarkers.
(J Thorac Oncol. 2010;5: 1279–1284)
Small cell lung cancer (SCLC) accounts for approximately13% of all cases of lung cancer in the United States.1
Platinum-based chemotherapy is the mainstay of treatment
for patients with SCLC. Although chemotherapy is associated
with a high response rate, the disease recurs in nearly all
patients with extensive-stage disease.2 Topotecan, a topo-
isomerase 1 inhibitor, is the only Food and Drug Adminis-
tration-approved agent for second-line therapy for SCLC.3
Topotecan demonstrated symptom improvement when com-
pared with combination chemotherapy and survival benefit
when compared with best supportive care.3,4 However, its
efficacy is restricted to patients with initial sensitivity to
platinum-based chemotherapy. Given the poor outcomes as-
sociated with SCLC, evaluation of other novel agents for the
treatment of SCLC is an urgent priority.
Angiogenesis is critical to the growth and sustenance of
cancer.5 Vascular endothelial growth factor (VEGF) is an
important mediator of angiogenesis in both physiological
circumstances and in the milieu of cancer. Studies conducted
in patients with SCLC have linked circulating concentrations
of VEGF with prognosis.6–10 Patients with a lower level of
circulating VEGF were more likely to respond to chemother-
apy compared with those with higher levels of VEGF.7 The
survival rates were inferior for patients with high VEGF
concentrations. Studies have also demonstrated a strong cor-
relation between VEGF expression and tumor microvessel
density in SCLC.8 In patients with resected SCLC, VEGF
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overexpression has been shown to correlate with microvessel
density, nodal and pathologic stage, and poor outcome.9,10
The results from these studies suggest that VEGF may be
linked to poor outcome in SCLC. Therefore, inhibition of
VEGF represents a rational therapeutic strategy for evalua-
tion in SCLC.
Treatment with either an anti-VEGF monoclonal anti-
body or a VEGF receptor tyrosine kinase inhibitor results in
inhibition of new blood vessel formation, regression of tumor
growth, and improved survival in preclinical models.11
Cediranib (AZD 2171, Recentin) is a potent and selective
inhibitor of the VEGF receptors 1, 2, and 3.12 It has demon-
strated anticancer activity in a variety of preclinical mod-
els including lung cancer. It has a high bioavailability with
oral administration. The recommended phase II dose of
cediranib was 45 mg PO once a day as monotherapy when
given on a continuous daily schedule.13 In phase I studies,
cediranib demonstrated anticancer activity in a variety of
solid organ malignancies.13,14 Therefore, we conducted a
phase II study of cediranib for patients with recurrent and/or
refractory SCLC.
PATIENTS AND METHODS
Patient Eligibility
Patients with SCLC that progressed with one prior
regimen (platinum-based chemotherapy) were eligible re-
gardless of the type of response to first-line therapy. Other
salient eligibility criteria were the presence of measurable
disease, Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 0 to 2, age older than 18 years, and
the ability to take oral medications on a regular basis. Qual-
ifying laboratory criteria were as follows: leukocytes 3000/
l; absolute neutrophil count 1500/l; platelet count
100,000/l; serum total bilirubin less than or equal to
institutional upper limit of normal (ULN); serum transami-
nases 2.5  ULN; and serum creatinine less than ULN.
Exclusion criteria were as follows: known brain metastasis,
mean QTc interval more than 500 milliseconds (with Bazett’s
correction) in screening electrocardiogram, history of familial
long QT syndrome, proteinuria more than 1 on two con-
secutive dipsticks taken no less than 1 week apart, class III or
IV heart failure (New York Heart Association) and those
requiring concurrent use of drugs with proarrhythmic poten-
tial, presence of severe intercurrent illness, pregnancy, lacta-
tion, patients taking antiretroviral therapy for HIV disease,
use of any other investigational agent within 30 days before
registration, and concomitant use of nephrotoxic drugs. Pa-
tients who had chemotherapy, radiotherapy, or major surgery
within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
before study entry or those who have not recovered from
adverse events from agents administered more than 4 weeks
earlier were excluded. The study protocol was approved by
the institutional review board of each participating institution.
All patients signed an informed consent form.
Treatment Plan
Cediranib was administered at the dose of 45 mg PO
once a day for the first 12 patients enrolled to the study.
Because seven of these patients were unable to complete the
first cycle of therapy due to intolerance, the protocol was
amended to reduce the dose of cediranib to 30 mg PO once a
day for subsequent patients. The drug was administered on a
daily continuous oral schedule. Patients were instructed to
take cediranib either 1 hour before or 2 hours after a meal.
Each treatment cycle consisted of 4 weeks of therapy. Treat-
ment cycles were continued until disease progression, unac-
ceptable toxicity, or withdrawal of informed consent. Patients
were asked to complete a pill diary to document intake of
the medication. Radiographic studies were performed ev-
ery two cycles of therapy to assess response. The RECIST
criteria were used to classify response. Toxicity was graded
by the National Cancer Institute Common Terminology Cri-
teria version 3.0.
Dose Modifications for Toxicity
Dose modifications were done for toxicity attributable
to cediranib. All toxicities were to have improved to grade 1
or less before initiation of each cycle of therapy. In the event
of toxicity, the dose of cediranib was reduced by one dose
level to 30, 20, or 10 mg once a day from the initial dose.
Expected grade 1 toxicities such as proteinuria, hypertension,
or hemorrhage were treated with dose reduction by one level.
For other grade 1 or 2 toxicities, dose reduction by one level
was done if the symptoms did not improve with appropriate
supportive care measures. For grade 3 or higher nonhemato-
logical toxicity and grade 4 hematological toxicity related to
cediranib, the dose was reduced by one dose level if symp-
toms did not resolve to grade 2 or less within 48 hours of
appropriate supportive care measures. A maximum of two
dose reductions were permitted for each patient. Delay in
initiation of therapy for longer than 2 weeks due to toxicity
resulted in removal from the study. Cediranib was discontin-
ued permanently if patients developed reversible posterior
leucoencephalopathy syndrome or symptomatic heart failure.
Patients were provided with a blood pressure monitor
and asked to check their blood pressure twice daily. If two
consecutive measurements were more than 140/90 mm Hg,
they were instructed to call the physician. Guidelines for
management of hypertension with appropriate antihyperten-
sive therapy were included in the study protocol. Cediranib
was held for grade 3 hypertension, and appropriate antihy-
pertensive therapy was initiated. Treatment was resumed only
after recovery to grade 1 or less.
Patient Evaluations
Baseline evaluations were conducted within 1 week
before initiation of protocol therapy. A history and physical
examination, complete blood count with differential, serum
chemistry, vital signs, serum pregnancy test for women of
child bearing potential, and assessment of PS were required at
baseline. Radiographic studies including computerized axial
tomography scan were performed within 4 weeks before
study entry and every two cycles subsequently. Toxicity was
assessed before the initiation of every cycle and on an as
needed basis. Bone scans and magnetic resonance imaging
scans were only required when prompted by appropriate
symptoms. Routine imaging of the brain was not necessary in
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asymptomatic patients. Serum levels of troponin-T and tro-
ponin-I was measured at baseline and after every two cycles
of therapy if clinically indicated. Serum thyroid stimulating
hormone and T4 levels were measured at baseline and with
every two cycles of therapy. Urine dipstick test for evaluation
for proteinuria was done once a week during study therapy.
An echocardiogram or a multiple gated acquisition scan was
done at baseline for patients at risk for impaired cardiac
function and every two cycles if clinically indicated.
Correlative Studies
Magnetic Separation of Circulating Endothelial Cells
Peripheral blood was to be collected in 10 ml ethyl-
enediaminetetraacetic acid tubes at baseline, day 15, and at
the week 10 of assessment. Participation in this part of the
study was optional. Tubes were immediately placed on wet
ice and shipped or stored overnight at approximately 4°C. On
arrival, the exact quantity of blood was recorded, transferred
into CPT Vaccutainer tubes, and centrifuged to exclude
granulocytes. Buffy coats were collected, washed, and fixed
in 2% paraformaldehyde. Cells were stored at 4°C and
analyzed within 2 weeks from the date received. Magnetic
separation and exclusion of CD45-positive cells was per-
formed to enrich for a nonhematopoietic fraction of white
blood cells (WBCs) (CD45-microbeads, Miltenyi Biotec,
Bergisch Gladbach, NRW, Germany) and passed through a
magnetic column of a MACS Separation Unit according to
the manufacturer’s protocol (all magnetic separation products
from Miltenyi Biotec). Both the negative and positive frac-
tions were collected and counted using Z1 Series Coulter
Counter Cell and Particle Counter (Beckman Coulter, Inc.,
Fullerton, CA). Three counts were performed for each frac-
tion. The ratio of CD45-negative cells per total WBCs and
concentration per volume of blood were established. After
magnetic separation, cells were cytospun onto positively
charged Superfrost Plus microscope slides (Fisher Scientific,
Inc., Waltham, MA) using a Shandon Cytospin 2 centrifuge
(Thermo, Inc., Waltham, MA). After washing, slides were
incubated with fluorescein isothiocyanate-conjugated anti-
CD146 antibody (cat. #MAB16985F, Chemicon International,
Inc., Billerica, MA), phycoerythrin-conjugated anti-CD133
antibody (cat. #130-080-801, Miltenyi Biotec), and counter-
stained with 4,6-diamidino-2-phenylindole (DAPI) (Sigma,
St. Louis, MO). Cells were observed on an Olympus BX61
Motorized Research Microscope (Olympus America, Inc.,
Centre Valley, PA) equipped with a fluorescent filter set and
analyzed by means of SlideBook 4.1 software (Intelligent
Imaging Innovations, Inc., Denver, CO). Positive and negative
cells were counted manually on each slide. Circulating endothe-
lial cells (CECs) were defined as CD45, CD146, and DAPI-
bright, with no less than 300 CD45 cells being counted.
Circulating endothelial progenitors (CEPs) were defined as
CD45, CD133, CD146, and DAPI-bright. Both the absolute
number and relative percentage of CECs and CEPs among
WBCs were determined. VEGF plasma levels were determined
using ELISA as previously reported.15
Statistical Methods
The primary end point of the study was determination
of the objective response rate with cediranib in patients with
refractory or recurrent SCLC. Secondary end points included
the assessment of toxicity, overall survival, and progression-
free survival. An objective response rate of 20% with
cediranib was required for further evaluation of the regimen,
whereas a response rate of 5% or less would be considered
not worthy of further study at this schedule and dose. The
Simon two-stage design was used. If at least one objective
response was seen in the first 12 patients, accrual would
continue to a maximum of 37 patients. The type I and II error
were 10% each with this sample size. Patients who received
at least one dose of the study drug were considered evaluable
for both toxicity and response.
RESULTS
A total of 25 patients were enrolled between March
2006 and December 2007. An interim analysis was conducted
after the first 12 patients were enrolled. Seven of 12 patients
did not complete even one cycle of therapy because of
treatment intolerance. The dose of 45 mg PO once a day was
deemed undeliverable for this patient population. However,
of the five patients who completed two cycles of therapy,
disease stabilization was noted in four. After discussion with
the coinvestigators and the Cancer Therapy Evaluation Pro-
gram of the National Cancer Institute, the study was amended
to reduce the dose of cediranib to 30 mg once a day and
restart the trial. The amended design was to follow the initial
design at the new dose of 30 mg but with the additional
provision that the study be stopped if more than 3 of the first
6 patients at 30 mg fail to complete their first course or if
more than 6 of the first 12 patients fail to complete their first
course. The results for patients enrolled to both dose levels
are reported.
Patient Characteristics
A total of 25 patients with a median age of 61 years
were enrolled (Table 1). Thirteen patients were treated at a
dose of cediranib 30 mg PO once a day. The majority of the
patients had an ECOG PS of 0 or 1. One patient had an ECOG
PS of 2. Twenty-three patients were of Caucasian ethnicity.
All patients had received prior platinum-based chemotherapy.
Eleven patients had received prior radiotherapy.
TABLE 1. Patient Baseline Characteristics
All
Patients
45 mg
(Once a Day)
30 mg
(Once a Day)
N 25 12 13
Median age (yr) 61 63 63
Male (N) 13 5 8
ECOG PS 0/1/2 (N) 12/12/1 6/6/0 6/6/1
Prior radiotherapy (N) 11 4 7
ECOG PS Eastern Cooperative Oncology Group performance status.
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Toxicity
The median number of cycles administered for patients
treated at the 45 mg dose PO once a day was less than one
cycle (range, 1–5). The reasons for discontinuation of therapy
during cycle 1 were as follows: grade 3 fatigue (n  3),
elevated liver enzymes (n  2), grade 3 hypertension (n  1)
and death due to progressive disease (n  1). Tolerance of
cediranib was better with the 30 mg dose with 8 of 13 patients
completing the first two cycles of therapy. The median
number of cycles at the lower dose was 2 (range, 1–8).
Common grade 1 or 2 toxicities were nausea, emesis, fatigue,
diarrhea, proteinuria, and hypertension (Tables 2 and 3).
Hypothyroidism was noted in two patients whereas one
patient developed hyperthyroidism. Three patients died of
progressive disease within 30 days of the last day of study
therapy.
Efficacy
No objective responses were noted at either of the dose
levels of cediranib. Stable disease was observed in nine
patients with five and four for the 45 mg and 30 mg dose of
cediranib, respectively. One patient met criteria for partial
response after cycle 2 of therapy, but the scan after cycle 4
demonstrated disease progression (Table 4). The lack of any
confirmed objective responses resulted in the closure of the
study after stage I of the accrual. The median progression-
free survival and the median overall survival were 2 and 6
months, respectively. At the 30 mg dose level, the median
progression-free survival and median overall survival were 2
and 4 months, respectively.
Correlative Studies
Pretreatment and ontreatment specimens were available
in a subset of patients only, and the results are considered
anecdotal. Because of the limited sample size and lack of
clinical activity, no conclusions could be drawn concerning
the relationship between numbers of CECs, VEGF plasma
levels, and treatment efficacy. We had hypothesized that
treatment with cediranib would result in a decrease in viable
CECs, particularly in responding patients. Five patients had
adequate specimens at baseline and at progression. Four of
five patients showed an increase in CECs per milliliter of
blood on progression, with two patients exhibiting sharp
increases (more than fivefold) after maintaining baseline
levels while on treatment (Figure 1). In two patients, only
baseline and progression specimens were available; however,
CECs in these patients went from low undetectable at base-
line to more than 120/ml at progression. In seven patients
with serial VEGF levels, discernable trends in plasma levels
were not detected with therapy nor were baseline levels
informative.
TABLE 2. Toxicitya
Toxicity Grade 1/2/3/4 (N)
Albumin 4/0/0/0
Alkaline phosphatase 3/1/0/0
Alanine aminotransferase 2/1/2/0
Anorexia 5/7/1/0
Aspartate aminotransferase 3/1/1/0
Constipation 4/1/0/0
Creatinine 2/2/0/0
Dehydration 0/3/0/0
Diarrhea 7/5/2/0
Dry mouth 4/0/0/0
Dyspnea 1/3/1/1
Fatigue 6/4/6/2
Hair loss 2/1/-/-
Hemoglobin 1/1/0/0
Hemorrhage 1/1/0/0
Hypertension 3/7/3/0
Infection with grade 1/2 ANC 1/2/0/0
Leukocytes 1/1/0/0
Lymphopenia 0/0/3/0
Mucositis 2/2/0/0
Muscle weakness 2/5/1/0
Nausea 10/1/0/0
Pain 3/6/1/0
Platelets 2/1/0/0
Proteinuria 5/2/3/0
Rash 3/0/0/0
Rash (hand-foot syndrome) 2/0/1/0
Sodium (low) 2/0/0/0
Thyroid function (low) 1/1/0/0
Voice changes 6/1/0/0
Vomiting 4/1/0/0
Weight loss 3/2/0/0
a Events those were possible, probable, or definitely related to study therapy in
more than one patient is presented in alphabetic order.
ANC, absolute neutrophil count.
TABLE 3. Grade 3/4 Toxicity by Dose Level
Toxicity
45 mg (Once a Day),
Grade 3/4 (N  12)
30 mg (Once a Day),
Grade 3/4 (N  13)
ALT/AST 2/0 1/0
Fatigue 2/2 4/0
Diarrhea 2/0 —
Hypertension 1/0 2/0
Proteinuria 2/0 1/0
Hand-foot syndrome 1/0 —
a Events those were possible, probable or definitely related to study therapy.
ALT, alanine aminotransferase; and AST, aspartate transaminase.
TABLE 4. Efficacy
All
Patients
(N)
45 mg
(Once a Day)
(N)
30 mg
(Once a Day)
(N)
Objective response 1a 0 1a
Stable disease 9 5 4
Progression 14 6 8
N/A 1 1 0
Median PFS (mo) 2 2 2
Median survival (mo) 6 6 4
a Unconfirmed response.
PFS, progression-free survival.
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DISCUSSION
Inhibition of angiogenesis has been successful as a
treatment strategy in a variety of solid organ malignancies.
Cediranib is a highly selective and potent inhibitor of the
VEGF receptor. This study was conducted to investigate the
utility of inhibiting the VEGF receptor in patients with
recurrent or relapsed SCLC for whom the overall prognosis is
poor. Although disease stabilization was noted in a few
patients, there were no objective responses. One patient had
reduction a partial response after two cycles, but the tumor
progressed quickly thereafter. The study did not meet the
efficacy criteria to proceed to full accrual after the interim
analysis. Sorafenib, another small molecule VEGF receptor
inhibitor, has also demonstrated comparable results as mono-
therapy in a study by the Southwest Oncology Group (SWOG
0435).16 Although objective responses were noted in a few
patients, the median progression-free survival and overall
survival of 2 and 5 to 7 months (platinum-refractory and
sensitive patients) were similar to the results with cediranib in
our study. When evaluated in the maintenance setting after
platinum-based therapy,17 vandetanib, a dual inhibitor of the
VEGF receptor and endothelial growth factor receptor tyrosine
kinases, failed to improve outcome. Taken together, these
results indicate that VEGF tyrosine kinase inhibitors are not
suited for monotherapy of SCLC. The Southwest Oncology
Group has recently initiated a phase II study with the com-
bination of cisplatin, etoposide, and cediranib (20 mg PO
once a day) for first-line therapy for extensive stage SCLC.
Our study also illustrated the difficulty of administering
cediranib at the originally recommended dose of 45 mg PO
once a day, because only 5 of the first 12 patients were able
to complete just 1 month of treatment. When the dose was
reduced to 30 mg once a day for subsequent patients, the
tolerance was better. In a study for patients with non-small
cell lung cancer, cediranib at the 45 mg dose in combination
with carboplatin and paclitaxel was not tolerated well, leading to
its dose reduction to 30 mg as in our study and furthermore to a
second reduction to 20 mg for further development of this
regimen.18
Bevacizumab, a monoclonal antibody against VEGF,
has also been tested in combination with chemotherapy by
two single-arm, phase II studies.19,20 Although the treat-
ment was tolerated well, the efficacy was modest with a
median survival of approximately 11 months. Given the
underwhelming efficacy with antiangiogenic agents in
SCLC, it is hoped that the identification of predictive
biomarkers might lead to optimal utilization of these
agents. The role of CECs in prediction of response to
antiangiogenic agents has become an important area of
research. In the current study, a trend toward increase in
CECs was noted at the time of progression in four of five
patients in whom samples were available. Similar findings
were noted by Beerepoot et al.21 in a study that demon-
strated higher CECs in patients with progressive malig-
nancy compared with those with stable disease or healthy
volunteers. However, Norden-Zfoni et al.22 noted an in-
crease in CECs during therapy with sunitinib among pa-
tients who derived clinical benefit. The identification of
distinct subtypes of CECs including the progenitor cells
and mature cells indicates the degree of complexity and the
need for additional studies with this marker in patients
receiving antiangiogenic therapy. Recently, certain genetic
polymorphisms in VEGF have been linked with a favor-
able outcome with bevacizumab.23 The relevance of this
marker to VEGF tyrosine kinase inhibitors is unknown.
FIGURE 1. Numbers of circulating endothelial cells (defined as CD45, CD146, CD133, and 4,6-diamidino-2-phenylin-
dole bright with viable nuclei), with day 1 draw immediately before initiation of first cycle of treatment and the final draw at
time of disease progression.
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In summary, the treatment of SCLC continues to be a
major challenge with a clear need to study new targets and
approaches.
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